Direkt zum Inhalt
Merck
Alle Fotos(1)

Key Documents

View All Documentation

F2756

Sigma-Aldrich

Fluorescein di(β-D-galactopyranosid)

Synonym(e):

FDG

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C32H32O15
CAS-Nummer:
17817-20-8
Molekulargewicht:
656.59
MDL-Nummer:
MFCD00077344
UNSPSC-Code:
12352201
PubChem Substanz-ID:
24894829
NACRES:
NC.07

Assay

≥98% (HPLC)

Qualitätsniveau

100

Form

powder

Löslichkeit

methanol: 20 mg/mL, clear, yellow

Lagertemp.

−20°C

SMILES String

OC[C@H]1O[C@@H](Oc2ccc3c(Oc4cc(O[C@@H]5O[C@H](CO)[C@H](O)[C@H](O)[C@H]5O)ccc4C36OC(=O)c7ccccc67)c2)[C@H](O)[C@@H](O)[C@H]1O

InChI

1S/C32H32O15/c33-11-21-23(35)25(37)27(39)30(45-21)42-13-5-7-17-19(9-13)44-20-10-14(43-31-28(40)26(38)24(36)22(12-34)46-31)6-8-18(20)32(17)16-4-2-1-3-15(16)29(41)47-32/h1-10,21-28,30-31,33-40H,11-12H2/t21-,22-,23+,24+,25+,26+,27-,28-,30-,31-/m1/s1

InChIKey

ZTOBILYWTYHOJB-WBCGDKOGSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Anwendung

Fluorescein di(β-D-galactopyranoside) (FDG) has been used for the detection of gene expression via FACS (fluorescence-activated cell sorting).
Fluorescein di(β-D-galactopyranoside) has been used as a substrate in β-galactosidase assay.

Biochem./physiol. Wirkung

Fluorescein di (β-D-galactopyranoside) (FDG) results in fluorescence after being hydrolyzed to fluorescein by β-galactosidase. It gives fluorescence proportional to the enzymatic activity. This molecule is mainly required for the detection of gene expression in transfected cells when using β-galactosidase (Lac Z) as a reporter gene.

Substrate

Fluorogenic substrate for β-galactosidase

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

94433

β-Galaktosidase-Färbung

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable

Persönliche Schutzausrüstung

Eyeshields, Gloves, type N95 (US)

Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Kunden haben sich ebenfalls angesehen

Slide 1 of 1

1 of 1

Bafilomycin A1 aus Streptomyces griseus ≥90% (HPLC)

Sigma-Aldrich

B1793

Bafilomycin A1 aus Streptomyces griseus

Michael Peter Jones et al.
Radiation oncology (London, England), 14(1), 140-140 (2019-08-08)
To investigate the prognostic significance of positron emission tomography (PET) parameters from F-18 fluorodeoxyglucose (FDG) PET scans performed pre- and post- chemo-radiotherapy (CRT) for squamous cell carcinoma of the anal canal (AC). From January 2013 to January 2017, 19 patients
Jose M Anton-Rodriguez et al.
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 40(6), 826-835 (2019-04-30)
To investigate whether [F]fluorothymidine (FLT) and/or [F]fluorodeoxyglucose (FDG) positron emission tomography (PET) can differentiate growth in neurofibromatosis 2 (NF2) related vestibular schwannomas (VS) and to evaluate the importance of PET scanner spatial resolution on measured tumor uptake. Six NF2 patients
Dominik Berzaczy et al.
Cancers, 12(1) (2019-12-22)
The response evaluation criteria in lymphoma (RECIL) classification for lymphoma treatment response assessment was introduced in 2017, but it has not yet been compared to the established Lugano classification. Also, the value of the provisional "minor response" (MiR) category of
Tamio Furuse et al.
Disease models & mechanisms, 12(9) (2019-08-11)
Dysfunction of glucose transporter 1 (GLUT1) proteins causes infantile epilepsy, which is designated as a GLUT1 deficiency syndrome (GLUT1DS; OMIM #606777). Patients with GLUT1DS display varied clinical phenotypes, such as infantile seizures, ataxia, severe mental retardation with learning disabilities, delayed
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance.
David Lh Chan et al.
Theranostics, 7(5), 1149-1158 (2017-04-25)
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.